Two highly hydroxylated 1,3-dihydroisobenzofurans, FR198248 (1) and FR202306 (2), were isolated as peptide deformylase (PDF) inhibitors from Aspergillus flavipes. Compounds 1 and 2 inhibited Staphylococus aureus PDF with IC 50 values of 3.6 and 2.5 M, respectively, and also showed antibacterial activity with an MIC value of 25 g/ml. In contrast, 6-O-methyl derivative 3 of compound 2 was inactive against both PDF and S. aureus.
The emergence of antibiotic-resistant bacteria has steadily increased in recent years to become a serious threat to humans. This emphasizes the need to discover and develop novel antibacterial drugs with new modes of action. 1) Bacterial genomics has revealed a plethora of previously unknown targets of potential use in the discovery of novel antibacterial drugs.
2) One novel antibacterial target that has been receiving an increasing amount of attention is the bacterial peptide deformylase (PDF) (EC 3.5.1.31). 3, 4) PDF, a member of a unique subclass of metalloenzymes, catalyzes the removal of the formyl group at the N-terminus of bacterial proteins. PDF that is essential for bacterial growth is present in all clinically relevant bacteria and is highly conserved, but not required by mammalian cells, which potentially makes it possible to identify a selective mechanismbased antibacterial agent without toxicity. Recent studies by several research groups have shown that PDF inhibitors acted as broad-spectrum antibacterial agents. 3, 5, 6) Some PDF inhibitors have already been reported, although most of them were peptidic. [7] [8] [9] [10] [11] In the course of our screening for new PDF inhibitors from microbial resources, highly hydroxylated 1,3-dihydroisobenzofurans, FR198248 (1) and FR202306 (2), were isolated from liquid fermentation cultures of the fungus, Aspergillus flavipes F543. Compound 1 that had previously been isolated from Aspergillus terreus was reported to have anti-influenza activity. 12, 13) Compound 2, a methyl acetal of compound 1, was an artifact formed during the isolation procedure with methanol. Compound 1 is very rare metabolite and its antibacterial activity has not yet been reported. We present in this paper the isolation and PDF-inhibitory and antibacterial activities of compounds 1 and 2 compared with dimethylated derivative 3 of compound 1 (Fig. 1) .
Fungal strain F543 was isolated from soil collected in Chungbuk Province, South Korea. The EtOAc extract of liquid fermentation cultures of strain F543 was fractionated by silica gel and Sephadex LH-20 column chromatography. Final separation of the active fraction by reversed-phase HPLC afforded two active compounds 1 and 2.
The 1 H-and 13 C-NMR spectra of compound 1 indicated the presence of a highly hydroxylated benzene ring. The 1 H-and 13 C-NMR data for compound 1 independently assigned by the HMBC spectrum in DMSO-d 6 were identical with those of FR198248. 13) Although the NMR data for compound 1 in CD 3 OD were also identical with the data for FR198248 reported in the literature, 13) we could confirm that those data should be revised to the NMR data of the deuterated methyl acetal of compound 1 found in this study. The 1 H-and 13 C-NMR data for compound 2 were also identical with those of FR202306 reported in the literature. 13) In addition, the HMBC correlation from the methoxy protons at 3.20 to the acetal methine carbon at 106.3 confirmed the linkage of the methoxy group to C-1. Thus, compounds 1 and 2 were respectively determined to be FR198248 and FR202306 (Fig. 1 ). Since compound 2 was not detected in the EtOAc extracts of the fermentation cultures (data not shown) and was formed from compound 1 in methanol ( Fig. 2A) , compound 2, a methyl acetal of compound 1, was an artifact produced during the isolation procedure with methanol. To see whether the hydroxyl groups in compound 1 affected its activity, methylation of compound 1 was carried out. Compound 1 was dissolved in methanol to afford compound 2, which in turn was methylated with diazomethane to yield compound 3. The 1 H-and 13 C-NMR spectroscopic data for compound 3 showed the presence of two additional methoxy signals (3H, s, H 3.35; C 53.4 and 3H, s, H 3.75; C 60.6). The methoxy protons at 3.75 and 3.35 were respectively long-range coupled to the aromatic carbon at 134.6 (C-6) and to the acetal methine carbon at 106.6 (C-1) in the HMBC spectrum. Additionally, the methyl protons at 1.97 (8-CH 3 ) showed HMBC correlations with the aromatic carbons at 108.7 (C-4), 135.2 (C-3a), and 148.9 (C-5), while the methylene proton at 4.84 (H-3 b ) was long-range coupled to the aromatic carbon at 114.2 (C-7a), C-3a, C-4, and C-1. Considering the 13 C-NMR chemical shifts of C-6, these data indicated the presence of methoxy groups at C-1 and C-6. Thus, the structure of compound 3 was determined as the new 1,6-O-dimethyl derivative of compound 1 shown in Fig. 1 .
Compound 1 strongly inhibited S. aureus PDF in a dose-dependent fashion with an IC 50 value of 3.6 mM ( Table 1) . Compound 2, an 1-O-methyl derivative of compound 1, showed similar potency against S. aureus PDF to compound 1 with an IC 50 value of 2.5 mM. The stability of the methyl acetal portion of compound 2 in the assay buffer solution was examined by HPLC. As shown in Fig. 2B , 30% and 65% of compound 2 was converted to compound 1 at 3 and 10 min, respectively, after being dissolved in the buffer solution. However, in the kinetic experiment, the PDF-inhibition rate of compound 2 was similar to that of compound 1 (data not shown), suggesting that the PDF-inhibitory activity of compound 2 was similar to that of compound 1. This result indicates that methylation of the hydroxyl group at C-1 of compound 1 did not affect the activity of this compound. In contrast, compound 3, a 6-O-methyl derivative of compound 2, did not inhibit S. aureus PDF even at 100 mM. This indicates that methylation of the hydroxyl group at C-6 of compound 2 dramatically decreased its PDF-inhibitory activity.
To see whether compound 1 and 2 would show antibacterial activity, MICs against S. aureus, methicillin-resistant Staphylococcus aureus (MRSA), and quinolone-resistant Staphylococcus aureus (QRSA) were examined by using the microdilution broth method (Table 1) . Compounds 1 and 2 also exhibited the antibacterial activity against S. aureus RN4220, MRSA CCARM 3167, and QRSA CCARM 3505, with MICs of 25 mg/ml. Compound 3, however, did not exhibit any antibacterial activity against S. aureus RN4220, MRSA CCARM 3167, or QRSA CCARM 3505 even at 100 mg/ml, as expected. This data showed good correlation between the PDF-inhibition and antibacterial activity of compounds 1-3, suggesting that the antibacterial action of compound 1 may have been due to the inhibition of PDF.
The inhibition mechanism for compound 1 was investigated by a Lineweaver-Burk plot analysis. Compound 1 showed non-competitive inhibition against S. aureus PDF with respect to the substrate, f-MAS, with a K i value of 3.47 mM (data not shown). Actinonin as a positive control also showed non-competitive inhibition against S. aureus PDF with respect to the substrate in our system. 14) Several classes of PDF inhibitors, including actinonin, thiopeptides, BB3497, biaryl acids, VRC3324, andsulfinylhydroxamic acid, have been reported in the past few years. 3, 15) Most of them contain chelating groups, including hydroxamate, N-formyl hydroxyl, and thiol. Actinonin is a naturally occurring peptidic hydroxamic acid that was first isolated in 1962 from an actinomycete 16) and has recently been shown to be a PDF inhibitor, 14) although it has not been developed as a therapeutic agent due to its lack of in vivo efficacy. Some PDF inhibitors based on actinonin have been developed by several groups, but still have their potential lack of bioavailability or selectivity against other classes of human metalloproteases. 15) Some nonpeptidic and non-hydroxamic acids such as Sch 382582, 17) macrolactins, 18) and fumimycin 19) have been isolated as PDF inhibitors from microbial resources, but have been reported to have very weak antibacterial activity. Compounds 1 and 2 are also non-peptidic and non-hydroxamic PDF-inhibitors, but showed moderate antibacterial activity which could provide the potential for developing new anti-MRSA agents.
In conclusion, compounds 1 and 2 are highly hydroxylated 1,3-dihydroisobenzofurans. They strongly inhibited S. aureus PDF and also showed moderate antibacterial activity against S. aureus, as well as drugresistant S. aureus strains such as MRSA and QRSA. Compounds 1 and 2 may provide a useful chemical scaffold as a new class of PDF inhibitor for the development of new anti-MRSA agents.
Experimental
General. NMR spectra were recorded with a Bruker Biospin Avance 500 spectrometer (Korea Basic Science Institute), and HRESI-MS data were recorded by a Jeol JMS-HX110/110A mass spectrometer. Column chromatography was carried out on silica gel (Kieselgel 60, 70-230 mesh, Merck) and Sephadex LH-20 (Amersham Biosciences). HPLC was performed by a Waters system, using a reversed-phase ODS column (YMC C 18 , 10 Â 250 mm). Fermentation and isolation. Fermentation was carried out as a liquid culture in a YPS medium containing 2% glucose, 0.2% yeast extract, 0.5% peptone, 0.05% MgSO 4 , and 0.1% KH 2 PO 4 at pH 5.7 before sterilization. A piece of the strain F543 from a mature plate culture was inoculated into a 500-ml Erlenmeyer flask containing 80 ml of this sterile liquid medium and cultured on a rotary shaker (150 rpm) at 28 C for 3 d. To produce the active compounds, 15 ml of the seed culture was transferred into 1000-ml Erlenmeyer flasks containing 300 ml of the YPS medium, and cultivated on a rotary shaker (150 rpm) for 7 d at under 28 C. After this incubation, the fermented liquid culture (3-liter) was extracted with 80% acetone and centrifuged at 6370 g for 20 min. The supernatant was concentrated in vacuo to an aqueous solution, which was then extracted three times with an equal volume of EtOAc. The EtOAc extract (4.42 g) was subjected to silica gel column chromatography, using stepwise elution with To test the stability of compounds 1 and 2, 1 mg of each was respectively dissolved in 500 ml of MeOH at room temperature and the PDF-assay buffer (50 mM HEPES and 10 mM NaC, pH 7.5) at 30 C. Each 10 ml was sampled 1, 3, 10, 30, and 60 min after dissolution and then subjected to reverse-phase HPLC column chromatography (4:6 Â 250 mm, S-4 mm, YMC C 18 ) measured at 220 nm. The column was eluted with CH 3 CN-H 2 O (20:80) at a flow rate of 0.6 ml/min to afford compounds 1 and 2 with respective retention times of 4.0 and 6.1 min. The relative amounts of compounds 1 and 2 were calculated from their peak areas.
Methylation of compound 1. Compound 1 (23 mg) dissolved in MeOH (6 ml) was methylated with ethereal diazomethane (5 ml) at room temperature for 10 min and dried by nitrogen. The residue dissolved in MeOH was applied to SiO 2 TLC developed with CHCl 3 -MeOH (10:1) to afford compound 3 (4.1 mg) at an R f of 0.5 as a white powder. PDF assay. The assay of S. aureus PDF was carried out according to our previously reported method; 18) the assay mixture contained 50 mM HEPES (pH 7.5), 10 mM NaCl, 20 mg/ml of bovine serum albumin, 2 mM N-formylmethionine-alanine-serine (f-MAS), 20 mM NAD, 0.00025 unit of formate dehydrogenase, and 54.3 nM S. aureus PDF in half-area, 96-well microtitre plates. The compound dissolved in dimethyl sulfoxide was added to each well. The rate of increase in the amount of NADH in each reaction well was measured at 340 nm and 30 C by a microtiter ELISA reader, using SOFTmax PRO software (Molecular Devices, CA, USA). The inhibitory activity was calculated by the following formula: % of inhibition = 100 Â [1 À (rate in the presence of the compound/ rate in the untreated control)].
Determination of the antibacterial susceptibility. 20) S. aureus RN4220, MRSA CCARM3167 and QRSA CCARM 3505 were used. S. aureus was grown to the mid-log phase in Mueller-Hinton broth and diluted 1,000-fold in the same medium. The cells (10 5 /ml) were inoculated into the Mueller-Hinton broth and dispensed at 0.2 ml/well in a 96-well microtiter plate. MICs were determined in triplicate by serial dilution of each test compound. The MIC value is defined as the concentration of a test compound that completely inhibited cell growth at 30 C. Bacterial growth was determined by measuring the absorption at 650 nm with a microtiter ELISA reader.
